摘要:
A loader is disclosed that can load a suture and/or a shuttle into a suture device. The loader can have a suture and/or a shuttle that can be moved (e.g., via a loader control) from a non-loaded configuration to a loaded configuration without damaging the suture or the shuttle. The shuttle can be moved from a shuttle first position to a shuttle second position. When the shuttle is in the shuttle first position, a suture device can be positionable in a device space on the loader. When the suture device is positioned in the device space, the shuttle can be moved from the shuttle first position to the shuttle second position. When the shuttle is in the shuttle first position, the shuttle can be outside the suture device. When the shuttle is in the shuttle second position, the shuttle can be inside the suture device.
摘要:
It is an object of the present invention to provide a film-forming composition for skin (such as a film-type skin protectant or a film-type skin topical agent) that does not contain a lower monohydric alcohol such as ethanol or isopropanol, is excellent in quick-drying properties and water resistance, is less sticky, and is excellent in feeling of use. The present invention relates to a film-forming composition for skin which contains a specific acrylic polymer, a plasticizer and water and is substantially free of a lower monohydric alcohol such as ethanol or isopropanol. The composition of the present invention is extremely useful for treatment of chronic skin diseases (that is, skin diseases in which skin barrier function is deteriorated) represented by hand eczema, atopic dermatitis, and the like.
摘要:
Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1α,25-dihydroxyvitamin D3, medium-chain triglyceride, a nonionic surfactant, and a water-soluble thickener and a method of treatment of skin disorders using the same.
摘要:
An agent for treatment of pemphigoid is provided. For use as an agent for treatment of pemphigoid, IFN-γ is administered in a dose of 2,000,000 JRU once daily for 7 days by intravenous drip infusion. Depending on symptoms, side effects and age of a patient, the dose can be change, or the dosage can changed to intravenous drip infusion given once in several days. IFN-γ is fast-acting against pemphigoid, involves few side effects, and is considered to be effective. The mechanism of action is presumed to be that IFN-γ suppresses the chemotaxis and function of eosinophils which are considered to be directly involved in the occurrence of pemphigoid.
摘要:
An object of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blister or erosion, etc. For example, the present invention can provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and an alcohol and/or a fatty acid having 12 or more carbon atoms.
摘要:
A deformed nail corrector for correcting a deformed nail is provided that includes: a first elastic wire which has one end portion thereof fixed to one edge of the deformed nail in a width direction; a second elastic wire which has one end portion thereof fixed to the other edge of the deformed nail in the width direction; and a binding means which binds the first and second elastic wires to each other and is slidable along the first and second elastic wires in a bound state. The first and second elastic wires are brought into a state where the first and second wires are deformed along the deformed nail with the first and second, elastic wires being in a corrector mounting state where the first and second elastic wires are bound to each other by the binding means.
摘要:
The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.
摘要:
The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.
摘要:
In one embodiment, the present disclosure provides pharmaceutical compositions for suppressing the progression of fibrosis in systemic sclerosis, which contain an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides pharmaceutical compositions for suppressing Th2 polarization to suppress the progression of fibrosis in systemic sclerosis, which comprise an antibody against IL-31 receptor A as an active ingredient. In a certain embodiment, the above-mentioned antibody is an antibody having a neutralizing activity against IL-31 receptor A.
摘要:
The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing/treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.